Notably, NSD2 has been shown to increase global levels of H3K36me2 while reducing H3K27me3, leading to large-scale reprogramming of chromatin architecture and transcriptional output, particularly in malignancies such as multiple myeloma [32]. Here, NSD2 is linked to plasma cell myeloma.